140 related articles for article (PubMed ID: 23696114)
1. Serum sodium identifies patients with cirrhosis at high risk of hepatorenal syndrome.
Janičko M; Veselíny E; Abraldes JG; Jarčuška P
Z Gastroenterol; 2013 Jul; 51(7):628-34. PubMed ID: 23696114
[TBL] [Abstract][Full Text] [Related]
2. Predictors of hepatorenal syndrome in alcoholic liver cirrhosis.
Janicko M; Veseliny E; Senajova G; Jarcuska P
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Dec; 159(4):661-5. PubMed ID: 25820623
[TBL] [Abstract][Full Text] [Related]
3. MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation.
Londoño MC; Cárdenas A; Guevara M; Quintó L; de Las Heras D; Navasa M; Rimola A; Garcia-Valdecasas JC; Arroyo V; Ginès P
Gut; 2007 Sep; 56(9):1283-90. PubMed ID: 17452425
[TBL] [Abstract][Full Text] [Related]
4. Serum cystatin C in advanced liver cirrhosis and different stages of the hepatorenal syndrome.
Barakat M; Khalil M
Arab J Gastroenterol; 2011 Sep; 12(3):131-5. PubMed ID: 22055590
[TBL] [Abstract][Full Text] [Related]
5. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response.
Sharma P; Kumar A; Shrama BC; Sarin SK
Am J Gastroenterol; 2008 Jul; 103(7):1689-97. PubMed ID: 18557715
[TBL] [Abstract][Full Text] [Related]
6. [Serum sodium concentration profile for cirrhotic patients and its effect on the prognostic value of the MELD score].
Zhang JY; Qin CY; Jia JD; Wang BE
Zhonghua Gan Zang Bing Za Zhi; 2012 Feb; 20(2):108-11. PubMed ID: 22464781
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors for patients with cirrhosis and kidney dysfunction in the era of MELD: results of a prospective study.
Schepke M; Appenrodt B; Heller J; Zielinski J; Sauerbruch T
Liver Int; 2006 Sep; 26(7):834-9. PubMed ID: 16911466
[TBL] [Abstract][Full Text] [Related]
8. Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study.
Ghosh S; Choudhary NS; Sharma AK; Singh B; Kumar P; Agarwal R; Sharma N; Bhalla A; Chawla YK; Singh V
Liver Int; 2013 Sep; 33(8):1187-93. PubMed ID: 23601499
[TBL] [Abstract][Full Text] [Related]
9. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation.
Alessandria C; Ozdogan O; Guevara M; Restuccia T; Jiménez W; Arroyo V; Rodés J; Ginès P
Hepatology; 2005 Jun; 41(6):1282-9. PubMed ID: 15834937
[TBL] [Abstract][Full Text] [Related]
10. Cystatin C is a good predictor of hepatorenal syndrome and survival in patients with cirrhosis who have normal serum creatinine levels.
Ahn HS; Kim YS; Kim SG; Kim HK; Min SK; Jeong SW; Jang JY; Lee SH; Kim HS; Kim BS; Park JM
Hepatogastroenterology; 2012 Jun; 59(116):1168-73. PubMed ID: 22057374
[TBL] [Abstract][Full Text] [Related]
11. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.
Wong F; Pantea L; Sniderman K
Hepatology; 2004 Jul; 40(1):55-64. PubMed ID: 15239086
[TBL] [Abstract][Full Text] [Related]
12. Terlipressin in 30 patients with hepatorenal syndrome: results of a retrospective study.
von Kalckreuth V; Glowa F; Geibler M; Lohse AW; Denzer UW
Z Gastroenterol; 2009 Jan; 47(1):21-6. PubMed ID: 19156588
[TBL] [Abstract][Full Text] [Related]
13. An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis.
Luca A; Angermayr B; Bertolini G; Koenig F; Vizzini G; Ploner M; Peck-Radosavljevic M; Gridelli B; Bosch J
Liver Transpl; 2007 Aug; 13(8):1174-80. PubMed ID: 17663415
[TBL] [Abstract][Full Text] [Related]
14. Clinical value of increased serum creatinine concentration as predictor of short-term outcome in decompensated cirrhosis.
Serra MA; Puchades MJ; Rodríguez F; Escudero A; del Olmo JA; Wassel AH; Rodrigo JM
Scand J Gastroenterol; 2004 Nov; 39(11):1149-53. PubMed ID: 15545175
[TBL] [Abstract][Full Text] [Related]
15. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone.
Ruf AE; Kremers WK; Chavez LL; Descalzi VI; Podesta LG; Villamil FG
Liver Transpl; 2005 Mar; 11(3):336-43. PubMed ID: 15719386
[TBL] [Abstract][Full Text] [Related]
16. Identification of patients with decompensated cirrhosis at high risk for death: improving the prediction by hepatic venous pressure gradient?
Park SH; Park HY; Kang JW; Park JS; Shin KJ; Kim CH; Suk KT; Baik GH; Kim JB; Kim DJ; Lee HY
Hepatogastroenterology; 2012; 59(120):2548-51. PubMed ID: 23178621
[TBL] [Abstract][Full Text] [Related]
17. Long-term rifaximin therapy as a primary prevention of hepatorenal syndrome.
Ibrahim ES; Alsebaey A; Zaghla H; Moawad Abdelmageed S; Gameel K; Abdelsameea E
Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1247-1250. PubMed ID: 28902040
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of the relationship between hepatorenal syndrome and plasma ammonia].
He Y; Li GX; Xia Y
Zhonghua Gan Zang Bing Za Zhi; 2010 Jan; 18(1):45-8. PubMed ID: 20128969
[TBL] [Abstract][Full Text] [Related]
19. Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment.
Wong F; Raina N; Richardson R
Gut; 2010 Mar; 59(3):381-6. PubMed ID: 19710033
[TBL] [Abstract][Full Text] [Related]
20. Validation of model for end-stage liver disease score to serum sodium ratio index as a prognostic predictor in patients with cirrhosis.
Lv XH; Liu HB; Wang Y; Wang BY; Song M; Sun MJ
J Gastroenterol Hepatol; 2009 Sep; 24(9):1547-53. PubMed ID: 19686416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
